New hydrolyzable tannins, shephagenins A and B, from Shepherdia argentea as HIV-1 reverse transcriptase inhibitors. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


New hydrolyzable tannins, shephagenins A and B, from Shepherdia argentea as HIV-1 reverse transcriptase inhibitors.

Chem Pharm Bull (Tokyo). 1996 Aug;44(8):1436-9. Unique Identifier : AIDSLINE MED/96387794
Yoshida T; Ito H; Hatano T; Kurata M; Nakanishi T; Inada A; Murata H; Inatomi Y; Matsuura N; Ono K; Nakane H; Noda M; Lang FA; Murata J; Faculty of Pharmaceutical Sciences, Okayama University, Japan.

Abstract: Two new hydrolyzable tannins, shephagenins A and B, were isolated along with hippophaenin A and strictinin from the leaf extract of Shepherdia argentea, which showed a remarkable inhibitory activity against human immunodeficiency virus (HIV)-1 reverse transcriptase. Their structures, having a gluconic acid core, have been elucidated on the basis of spectroscopic and chemical methods. The inhibitory effect of the leaf extract on HIV-1 reverse transcriptase was found to be due to tannins, and their activities were stronger than that of (-)-epigallocatechin gallate as a positive control.
Keywords: Antiviral Agents/ISOLATION & PURIF/*PHARMACOLOGY Carbohydrate Sequence Human Hydrolysis HIV-1/*DRUG EFFECTS/*ENZYMOLOGY Molecular Sequence Data Nuclear Magnetic Resonance Plant Leaves/CHEMISTRY Plants, Medicinal/*CHEMISTRY Reverse Transcriptase Inhibitors/ISOLATION & PURIF/*PHARMACOLOGY Support, Non-U.S. Gov't Tannins/ISOLATION & PURIF/*PHARMACOLOGY JOURNAL ARTICLEKWDantiviralagents/isolation&purif/KWDpharmacologycarbohydratesequencehumanhydrolysishiv-1/KWDdrugeffects/KWDenzymologymolecularsequencedatanuclearmagneticresonanceplantleaves/chemistryplants,medicinal/KWDchemistryreversetranscriptaseinhibitors/isolation&purif/KWDpharmacologysupport,non-uKWDsKWDgov'ttannins/isolation&purif/KWDpharmacologyjournalarticle
970228
M9721902

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .